drugset
drugset / Trial / NCT04461587

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

NCT04461587 ↗

Phase 2 Completed 50 enrolled Pulmonary Research of Abingdon, LLC Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis (black lung) with pulmonary fibrosis (scarring of the lung).

Timeline

Start
2020-08-31
Primary completion
2022-11-10
Completion
2022-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirfenidone Small molecule 801 mg —

Indications

pneumoconiosis